CATT of course tested ranibizumab (Lucentis) as the control against bevacizumab (Avastin) and not aflibercept (Eylea) against bevacizumab (Lucentis).
Apologies. I was too late to edit my above post.
Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024, page-37
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
73.0¢ |
Change
0.020(2.82%) |
Mkt cap ! $898.6M | |||
| Open | High | Low | Value | Volume |
| 71.0¢ | 75.3¢ | 70.3¢ | $2.722M | 3.702M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 14000 | 72.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 73.5¢ | 93091 | 2 |
View Market Depth
| Last trade - 16.10pm 23/09/2024 (20 minute delay) ? |
| OPT (ASX) Chart |